Document:

Monaker Group, Inc. 10-K

Exhibit 10.35

 

PROMISSORY NOTE

 

	$750,000,000	May 16, 2016

 

FOR VALUE RECEIVED, the undersigned,
Crystal Falls Investments, LLC, a Florida Limited Liability Corporation, having an address at 1175 South US Highway 1, Vero
Beach, FL 32962 (“Borrower”), promises to pay to the order of MONAKER GROUP, INC. (“Lender”),
with an office at 2690 Weston Road, Suite 200, Weston, Florida 33331, the principal sum of SEVEN HUNDRED AND FIFTY THOUSAND
($750,000.00) DOLLARS (the “Principal Amount”), together with interest on the unpaid Profit Participation
and the Principal Amount thereof computed from the date of the executed MEMBERSHIP INTEREST PURCHASE AGREEMENT (the “Sale
Date”), at the rates provided herein until May 15, 2018 or such earlier date on which the Principal Amount becomes due
and payable as provided herein (the “Maturity Date”); provided, however, that from and after (i) the Maturity
Date, whether upon stated maturity, acceleration or otherwise, or (ii) the date on which the interest rate hereunder is increased
to the Default Rate (as hereinafter defined) as provided herein, such additional interest shall be computed at the Default Rate.

 

As used
herein, the term “Default Rate” shall mean a rate of interest of twelve percent (12.0%) per annum, but in no
event shall the Default Rate be in excess of the Maximum Rate (as hereinafter defined).

 

If any payment of Profit Participation
(due 7 days after the preceeding month) is not paid within five (5) days from the due date for such payment, a late charge equal
to ten percent (10%) of such overdue payment or the maximum amount permitted by applicable law shall automatically become due to
the holder of this promissory note (the “Note”), subject, however, to the limitation that late charges may be
assessed only once on each overdue payment. Said late charges do not constitute interest and shall constitute compensation to the
holder of this Note for collection and co-lender administration costs incurred hereunder. In addition, if any payment of principal,
Profit Participation or interest is not paid when due, the holder of this Note shall have the right, upon notice to Borrower, to
increase the rate of interest per annum on all amounts outstanding to the Default Rate and, upon said notice, such rate increase
shall be effective retroactively as of the date from which the interest component of such overdue payment began to accrue and shall
remain in force and effect for so long as such default shall continue. This paragraph shall not be construed as an agreement or
privilege to extend the due date of any payment, nor as a waiver of any other right or remedy accruing to the holder of this Note
by reason of any default.

 

Principal, interest and conversion
hereunder shall be as follows:

 

(a)          The
Note will be set at zero percent (0%) interest and instead the Note Holder will be entitled to Profit Participation on a monthly
basis. Profit Participation is defined as 20% of the net commissions received in
Nameyourfee.com each month with the amounts to be paid within 7 days following the preceeding month.

 

    

     

    

 

(b)          In
the even Profit Participation payments are not paid on a timely basis in 2 or more instances then in addition to the Profit Participation
payments, the Note will bear interest at an annual rate of twelve percent (12.0%) per annum effective from the date of the second
late payment.

 

(c)          All
principal, interest and other sums due hereunder shall be due and payable in full on the Maturity Date.

 

Each payment hereunder shall
be credited first to Lender’s collection expenses, next to late charges, next to unpaid interest, and the balance, if any,
to the reduction of the Principal Amount. The interest on this Note shall be calculated on the basis of a 30-day month and a 360-day
year.

 

(d)          The
lender will be granted the option to convert the note into common shares of the entity in the event the borrower becomes a publicly
traded company. In such a case the lender will have conversion rights to convert any or all of the note into common stock of the
corporation based upon the lowest price of the last equity funding and/or debt conversion to common equity. This right will continue
during the term of the note.

 

(e)          This
Note may be prepaid in whole or in part at any time, without penalty or premium,.

 

Borrower hereby waive all demands
for payment, presentations for payment, notices of intention to accelerate maturity, notices of acceleration of maturity, demand
for payment, protest, notice of protest and notice of dishonor, to the extent permitted by law. Borrower further waives trial by
jury. No extension of time for payment of this Note or any installment hereof, no alteration, amendment or waiver of any provision
of this Note and no release or substitution of any collateral securing Borrower’s obligations hereunder shall release, modify,
amend, waive, extend, change, discharge, terminate or affect the liability of Borrower under this Note.

 

Any forbearance by the holder
of this Note in exercising any right or remedy hereunder or under any other agreement or instrument in connection with the Loan
or otherwise afforded by applicable law, shall not be a waiver or preclude the exercise of any right or remedy by the holder of
this Note. The acceptance by the holder of this Note of payment of any sum payable hereunder after the due date of such payment
shall not be a waiver of the right of the holder of this Note to require prompt payment when due of all other sums payable hereunder
or to declare a default for failure to make prompt payment.

 

    

     

    

 

If this
Note is placed in the hands of an attorney for collection, Borrower shall pay all costs incurred and reasonable attorneys’
fees for legal services in the collection effort, whether or not suit be brought.

 

At the election of the holder
of this Note, all payments due hereunder may be accelerated, and this Note shall become immediately due and payable without notice
or demand, upon the occurrence of any of the following events (each an “Event of Default”): (1) Borrower fails
to pay on or before the date due, any amount of principal and/or Profit Participation payments and/or interest payable hereunder;
(2) Borrower fails to perform or observe any other term or provision of this Note with respect to payment; provided, however,
that Borrower shall be provided with a five (5) calendar day period to cure same. In addition to the rights and remedies provided
herein, the holder of this Note may exercise any other right or remedy in any other document, instrument or agreement evidencing,
securing or otherwise relating to the indebtedness evidenced hereby in accordance with the terms thereof, or under applicable law,
all of which rights and remedies shall be cumulative.

 

Notwithstanding anything to the
contrary contained herein, under no circumstances shall the aggregate amount paid or agreed to be paid hereunder exceed the highest
lawful rate permitted under applicable usury law (the “Maximum Rate”) and the payment obligations of Borrower
under this Note are hereby limited accordingly. If under any circumstances, whether by reason of advancement or acceleration of
the maturity of the unpaid principal balance hereof or otherwise, the aggregate amounts paid on this Note shall include amounts
which by law are deemed interest and which would exceed the Maximum Rate, Borrower stipulates that payment and collection of such
excess amounts shall have been and will be deemed to have been the result of a mistake on the part of both Borrower and the holder
of this Note, and the party receiving such excess payments shall promptly credit such excess (to the extent only of such payments
in excess of the Maximum Rate) against the unpaid principal balance hereof and any portion of such excess payments not capable
of being so credited shall be refunded to Borrower.

 

This Note is secured by, among
other things, the issued and outstanding shares of Name Your Fee, LLC (the “Collateral”) identified in the MEMBERSHIP
INTEREST PURCHASE AGREEMENT (the “Agreement”)for the shares of Name Your Fee, LLC, and is entitled to the benefits
and security thereof.

 

By its acceptance of Lender’s
shares in Name Your Fee, LLC pursuant to the Agreement and execution of this Note, Borrower acknowledges, agrees and confirms that
it has no defense, offset or counterclaim for any occurrence in relation to this Agreement and Borrower acknowledges that Lender
has complied with all of its obligations under the Agreement as of the date hereof.

 

    

     

    

 

All payments of principal and
interest hereunder are payable in lawful money of the United States of America and shall be made by wire transfer to the account
of Lender, as instructed, pursuant to wiring instructions to be provided to Borrower at Closing or to such other accounts as may
be instructed by Lender.

 

Borrower is hereby prohibited
from exercising against Lender, any right or remedy which it might otherwise be entitled to exercise against Lender, including,
without limitation, any right of setoff or any defense. Any other claim that Borrower may have, arising from or related to the
transaction evidenced by this Note and the Agreement shall be asserted only against the Lender.

 

This Note shall be binding on
the parties hereto and their respective heirs, legal representatives, executors, successors and assigns.

 

This Note shall be construed
without any regard to any presumption or rule requiring construction against the party causing such instrument or any portion thereof
to be drafted.

 

This Note shall be governed by
the laws of the State of Florida without regard to choice of law consideration. Borrower hereby irrevocably consents to the jurisdiction
of the courts of the State of Florida and of any federal court located in such State in connection with any action or proceeding
arising out of or relating to this Note or the Agreement.

 

This Note may not be changed
or terminated orally.

 

A determination that any portion
of this Note is unenforceable or invalid shall not affect the enforceability or validity of any other provision, and any determination
that the application of any provision of this Note to any person or circumstance is illegal or unenforceable shall not affect the
enforceability or validity of such provision to the extent legally permissible and otherwise as it may apply to other persons or
circumstances.

 

    

     

    

 

JURY TRIAL WAIVER. BORROWER
AGREES THAT ANY SUIT, ACTION OR PROCEEDING, WHETHER CLAIM OR COUNTERCLAIM, BROUGHT BY BORROWER OR THE HOLDER OF THIS NOTE ON OR
WITH RESPECT TO THIS NOTE OR ANY OTHER LOAN DOCUMENT OR THE DEALINGS OF THE PARTIES WITH RESPECT HERETO OR THERETO, SHALL BE TRIED
ONLY BY A COURT AND NOT BY A JURY. BORROWER AND LENDER EACH HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE ANY RIGHT TO
A TRIAL BY JURY IN ANY SUCH SUIT, ACTION OR PROCEEDING. BORROWER ACKNOWLEDGES AND AGREES THAT AS OF THE DATE HEREOF THERE ARE NO
DEFENSES OR OFFSETS TO ANY AMOUNTS DUE IN CONNECTION WITH THE LOAN. FURTHER, BORROWER WAIVES ANY RIGHT IT MAY HAVE TO CLAIM OR
RECOVER, IN ANY SUCH SUIT, ACTION OR PROCEEDING, ANY SPECIAL, EXEMPLARY, PUNITIVE, CONSEQUENTIAL OR OTHER DAMAGES OTHER THAN, OR
IN ADDITION TO, ACTUAL DAMAGES. BORROWER ACKNOWLEDGES AND AGREES THAT THIS PARAGRAPH IS A SPECIFIC AND MATERIAL ASPECT OF THIS
NOTE AND THAT LENDER WOULD NOT EXTEND CREDIT TO BORROWER IF THE WAIVERS SET FORTH IN THIS PARAGRAPH WERE NOT A PART OF THIS NOTE.

 

[Remainder of this page intentionally
left blank.]

 

    

     

    

 

IN WITNESS WHEREOF, the undersigned
has executed this Note on the date set forth above.

	 	 	 	 	 	 
	WITNESS:	 	BORROWER:
	 	 	 	 	 
	 	 	Crystal Falls Investments LLC
	 	 	 	 	, a
	 	 	Limited Liability company	 
	 	 	 	 	 
	 	 	By: 	 	 
	 	 	 	Name:	Ashvin Mascarenhas	 
	Name:	 	 	Title:	MGMRex10-1.htm

Exhibit 10.1 

 

Stock Option No:  000XXX

 

EMPLOYEE STOCK OPTION AGREEMENT

 

 

 

EMPLOYEE STOCK OPTION AGREEMENT, dated as of {GRANT DATE}  (this “Agreement”), by and between AVIRAGEN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and  {Name} (the “Optionee”). 

 

 

 

R E C I T A L S:

 

WHEREAS, the Company has previously adopted the Aviragen Therapeutics, Inc. 2016 Equity Incentive Plan (as amended, restated and/or supplemented from time to time, the “Plan”) in order to attract, retain and motivate service providers of the Company and its Subsidiaries, and so that such individuals may participate in the long-term growth of the Company and its Subsidiaries; and 

 

 

 

WHEREAS, the Company desires to grant to the Optionee an option to purchase a specified number of shares of the Company’s common stock, par value $0.10 per share (“Shares”) pursuant to the Plan and the terms and conditions contained in this Agreement. 

 

 

 

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the Company and the Optionee, intending to be legally bound, agree as follows: 

 

 

 

Section 1.     Grant of Option. The Company grants to the Optionee, pursuant to the Plan and the terms and conditions of this Agreement, an option to purchase that number of Shares and at the exercise price set forth on Schedule A (the “Option”). This Option shall have the tax status set forth on Schedule A. Because Schedule A designates this Option as a Non-Qualified Option, it shall be treated as such and shall not be treated as an Incentive Stock Option.

 

Section 2.     Term of Option. Unless earlier terminated pursuant to the Plan or the other provisions of this Agreement, the Option shall terminate at the close of business on the date specified on Schedule A as the Expiration Date (the “Expiration Date”).

 

(a)     (i) Except as otherwise provided in Section 2(d) and Section 2(e) below, upon the Optionee’s termination of employment with the Company or any Subsidiary for any reason whatsoever, the then unvested portion of the Option shall immediately terminate without any compensation, payment or other consideration due, and (ii) except as otherwise provided in Section 2(b), Section 2(c), Section 2(d) and Section 2(e) below, the portion of the Option that is then vested shall remain exercisable until the earlier of the 90th day following the date of such termination and the Expiration Date, and any part of the Option which is not exercised within such period shall terminate on the last day of such period without any compensation, payment or other consideration due. In the case of any contradiction between any provision of the Plan and the provisions of this Section 2, the provisions of this Section 2 shall control. Section 7.2 of the Plan shall not apply to this Option.

 

 

 

 

(b)     If the Optionee’s employment is terminated for Cause, the unexercised portion of the Option (whether or not vested) will terminate immediately upon the Optionee’s termination of employment, without any compensation, payment or other consideration due.

 

(c)     Except as otherwise provided in Section 2(e) below, if the Optionee’s employment with the Company or any Subsidiary terminates by reason of his or her death or Disability, then the portion of the Option which is then vested may be exercised at any time prior to the earlier of the Expiration Date and twelve (12) months after such termination of employment, and any part of the Option which is not exercised within such period shall terminate on the last day of such period without any compensation, payment or other consideration due. 

 

(d)     If at any time the Optionee’s employment is terminated by either the Company or a Subsidiary without Cause (but not due to the Optionee’s death or Disability), then any portion of the Option which is outstanding and unvested upon such termination shall become immediately vested upon such termination and the entire Option shall be exercisable through the earlier of the date that is 18 months after the date of such termination of employment and the Expiration Date, and any part of the Option which is not exercised within such period shall terminate on the last day of such period without any compensation, payment or other consideration due.

 

(e)     If upon or following a Change in Control, the Optionee’s employment is terminated as the result of the Optionee’s death or Disability or by the Optionee for Good Reason, then any portion of the Option which is outstanding and unvested upon such termination shall become immediately vested upon such termination and the entire Option shall be exercisable through the earlier of the date that is 18 months after the date of such termination of employment and the Expiration Date, and any part of the Option which is not exercised within such period shall terminate on the last day of such period without any compensation, payment or other consideration due.

 

(f)     For all purposes of this Agreement, the Optionee’s employment with the Company or any Subsidiary shall terminate at the time when the employment relationship between the Optionee and the Company or any Subsidiary is terminated for any reason, which time shall be conclusively determined by the Committee. No termination of employment shall be deemed to occur (i) when there is a simultaneous reemployment of the Optionee by the Company or any Subsidiary, (ii) at the discretion of the Committee, and subject to applicable law, when a leave of absence has been granted by the Company or a Subsidiary, and (iii) at the discretion of the Committee, when the termination is followed by the simultaneous establishment of a consulting relationship between the Company or a Subsidiary and the Optionee. The Committee, in its absolute discretion, shall determine the effect of all matters and questions relating to termination of employment, including, but not by way of limitation, the question of whether a termination of employment resulted from a discharge for Cause.

 

Section 3.     Vesting. The Option shall vest in installments as provided on Schedule A, conditioned on the Optionee’s continuous employment with the Company or any Subsidiary from the Date of Grant specified on Schedule A through and including the applicable vesting date. 

 

Section 4.     Manner of Exercise. 

 

(a)     To exercise the Option, the Optionee shall provide written notice of such exercise in the form provided in Annex 1 to the Secretary of the Company (or such other Person designated in writing by the Company for this purpose) at the Company’s then principal office. The notice shall specify the number of Shares for which the Option is being exercised and shall be accompanied by a payment to the Company in full of the aggregate exercise price (in accordance with the procedures set forth in Annex 1), plus the amount of the withholding taxes determined by the Company to be due upon the purchase of such number of Shares (unless the Committee shall have consented to the making of other arrangements with the Optionee with respect to the payment of such withholding taxes). Notwithstanding Section 6.1(c) of the Plan, if the Optionee desires to satisfy the exercise price due upon exercise of the Option by directing the Company to reduce the number of Shares deliverable upon such exercise, the Optionee shall only be entitled to satisfy the exercise price in such manner with the prior express written consent of the Committee.

 

 

 

 

(b)     Delivery of the notice of exercise shall constitute an irrevocable election to purchase the Shares specified in the notice, and the date on which the Company receives the notice accompanied by payment in full of the exercise price for the Shares covered by the notice and the applicable withholding taxes shall be the date as of which the Shares shall be deemed to have been issued.

 

(c)     To exercise the Option following the Optionee’s death, the Persons who acquire the right to exercise the Option must prove to the Committee’s satisfaction that they have duly acquired the Option and that they have paid (or have provided for payment of) any taxes, such as estate, transfer, inheritance or death taxes, payable with respect to the Option or the Shares to which it relates, in addition to satisfying the other terms and conditions set forth in this Agreement.

 

Section 5.     Transferability. If the Option granted is designated on Schedule A as an “Incentive Stock Option,” the Option may be transferred only by will or the laws of descent and distribution and may be exercised during the Optionee’s lifetime only by the Optionee. If this Option is designated on Schedule A as a “Non-Qualified Option,” the Option may be transferred in accordance with Section 12 of the Plan.

 

Section 6.     Withholding Taxes. Upon the exercise of the Option (or any portion thereof), the Optionee shall pay to the Company or a Subsidiary (or otherwise make arrangements satisfactory to the Committee for the payment of) the amount of the Federal, state, local, and foreign income, employment, and other taxes required, in the Company’s sole judgment, to be collected or withheld with respect to the Option. Except as provided below, such amount shall be paid to the Company or a Subsidiary in cash. In the Committee’s discretion, the Optionee’s tax obligations may be paid by the surrender of that number of whole Shares with a Fair Market Value (valued on the date of exercise) as shall be equal to, but does not exceed, the minimum statutory amounts required to be collected or withheld by the Company or any Subsidiary with respect to the exercise of the Option.

 

Section 7.     Lock-Up Period. The Optionee agrees that, if so requested by the Company or any representative of the underwriters (the “Managing Underwriter”) in connection with any firm commitment underwritten public offering of any securities of the Company under the Securities Act of 1933, as amended (the “Securities Act”), the Optionee shall not sell or otherwise transfer any Shares or other securities of the Company (other than any securities of the Company being registered in such offering) or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the Shares, without the prior written consent of the Company and the Managing Underwriter, commencing on the initial date that securities are offered for sale under such offering and continuing for up to 180 days (the “Market Standoff Period”) thereafter or such greater period as provided by FINRA Rule 2241. The Optionee further agrees to execute promptly such agreements as may be reasonably requested by the Managing Underwriter in connection with such offering that are not inconsistent with this Section and that are deemed reasonably necessary by such Managing Underwriter to further evidence or to give further effect hereto. The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such Market Standoff Period.

 

Section 8.     Rights in Shares Before Issuance and Delivery. The Optionee shall not have any rights as a stockholder of the Company with respect to the Shares underlying the Option unless and until such Shares have been issued to the Optionee as fully paid Shares. No adjustment shall be made for dividends, distributions, or other rights for which the record date is prior to the date the Shares are issued, except as provided in Section 8 of the Plan.

 

Section 9.     No Right to Employment. Nothing contained in this Agreement shall be construed to confer on the Optionee any right to continue as an employee or other service provider of the Company or any Subsidiary, or to derogate from any right of the Company or any Subsidiary to terminate the Optionee’s employment or other service at any time, for any reason.

 

 

 

 

Section 10.     Qualifications to Exercise. Notwithstanding anything in this Agreement to the contrary, in no event may the Option be exercisable if the Company shall, at any time and in its sole discretion, determine that (a) the listing, registration or qualification of any Shares otherwise deliverable upon such exercise is required upon any securities exchange or under any state, federal, or foreign law, or (b) the consent or approval of any regulatory body is necessary or desirable in connection with such exercise. In such event, such exercise shall be held in abeyance and shall not be effective unless and until such listing, registration, qualification or approval shall have been effected or obtained free of any conditions not acceptable to the Company (regardless of any termination of the Option prior to such listing, registration, qualification or approval). The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company’s legal counsel to be necessary to the lawful issuance and sale of any Shares subject to the Option shall relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority shall not have been obtained. The Company shall not be required to issue fractional Shares upon the exercise of the Option.

 

Section 11.     Conditions to Transfer. As a condition to the exercise of the Option, the Company may require the Optionee to satisfy any qualifications that may be necessary or appropriate, to evidence compliance with any applicable law or regulation and to make any representation or warranty with respect thereto as may be requested by the Company. The certificate issued to evidence such Shares may bear appropriate legends summarizing these restrictions.

 

Section 12.     Entire Agreement. This Agreement and the Plan contain the entire agreement between the parties with respect to the Option and supersede all prior agreements and understandings among the parties related to such matters.

 

Section 13.     Administration. All questions of interpretation concerning this Agreement, the Plan, or any other form of agreement or other document employed by the Company in the administration of the Plan or the Option shall be determined by the Committee. All such determinations by the Committee shall be final, binding, and conclusive upon all Persons having an interest in the Option, unless fraudulent or made in bad faith. In addition, all other actions, decisions, and determinations taken or made by the Committee in the exercise of its discretion pursuant to the Plan or the Option or other agreement(s) shall be final, binding and conclusive upon all Persons having an interest in the Option.

 

Section 14.     Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Company and its successors and assigns and upon the Optionee and his or her permitted transferees, heirs, executors, administrators and legal representatives.

 

Section 15.     Further Instruments. The parties to this Agreement agree to execute such further instruments and to take such further action as may reasonably be necessary to carry out the intent of this Agreement.

 

Section 16.     Amendment; Termination; Waiver. This Agreement may be amended or terminated, and its terms or covenants waived, only by a written instrument executed on behalf of the Company (as authorized by the Committee) and the Optionee.

 

Section 17.     Delivery of Documents and Notices. Any document relating to participation in the Plan or any notice required or permitted hereunder shall be given in writing and shall be deemed given (except to the extent that this Agreement provides for effectiveness only upon actual receipt of such notice) upon personal delivery, electronic delivery at the e-mail address, if any, provided for the Optionee by the Company or any Subsidiary, or upon deposit in the U.S. Post Office or foreign postal service, by registered or certified mail, or with a nationally recognized overnight courier service, with postage and fees prepaid, addressed to the other party at the address of the Company’s headquarters (with respect to the Company), the address of the Optionee in the records of the Company (with respect to the Optionee), or at such other address as such party may designate in writing from time to time to the other party.

 

 

 

 

Unless otherwise specified by the Optionee in writing, all documents relating to the Plan (including, without limitation, the Plan, this Agreement, the Plan prospectus and any reports of the Company provided generally to the Company’s stockholders) may be delivered to the Optionee electronically. Such means of electronic delivery may include the delivery of a link to a Company intranet or the internet site of a third party involved in administering the Plan, the delivery of the document via e-mail or other means of electronic delivery specified by the Company. In addition, if permitted by the Company, the Optionee may deliver electronically Schedule A and the Form of Exercise Notice attached as Annex 1 to the Company or to such third party involved in administering the Plan as the Company may designate from time to time.

 

The Optionee acknowledges that the Optionee has read this Section 17 and consents to the electronic delivery of the Plan documents. The Optionee acknowledges that he or she may request from the Company a paper copy of any documents delivered electronically at no cost to the Optionee by contacting the Company by telephone or in writing. The Optionee further acknowledges that the Optionee will be provided with a paper copy of any documents if the attempted electronic delivery of such documents fails. Similarly, the Optionee understands that the Optionee must provide the Company or any designated third party administrator with a paper copy of any documents if the Optionee’s attempted electronic delivery of such documents fails. The Optionee may revoke his or her consent to the electronic delivery of documents described in this Section or may change the electronic mail address to which such documents are to be delivered (if Optionee has provided an electronic mail address) at any time by notifying the Company of such revoked consent or revised e-mail address by postal service or electronic mail. The Optionee understands that he or she is not required to consent to electronic delivery of documents described in this Section 17.

 

Section 18.     Governing Law. This Agreement shall be construed and enforced in accordance with the laws of the State of Delaware, without giving effect to the principles of conflicts of law thereof.

 

Section 19.   JURISDICTION, WAIVER OF JURY TRIAL. BY ENTERING INTO THIS AGREEMENT, THE COMPANY AND THE OPTIONEE IRREVOCABLY SUBMIT TO AND ACCEPT GENERALLY AND UNCONDITIONALLY THE EXCLUSIVE JURISDICTION OF THE FEDERAL COURTS LOCATED IN FULTON COUNTY, GEORGIA (OR IF FEDERAL JURISDICTION DOES NOT EXIST, IN THE STATE COURTS LOCATED THEREIN) AND ALL DISPUTES RELATING TO THIS AGREEMENT OR THE PLAN SHALL BE HEARD EXCLUSINVELY IN SUCH COURTS. THE COMPANY AND THE OPTIONEE HEREBY ACCEPT SERVICE OF PROCESS PURSUANT TO THE LAWS OF THE STATE OF GEORGIA AND THE RULES OF ITS COURTS, WAIVE ANY DEFENSE OF FORUM NON CONVENIENS AND AGREE TO BE BOUND BY ANY JUDGMENT RENDERED BY SUCH COURTS ARISING OUT OF, RELATED TO, OR IN CONNECTION WITH, THIS AGREEMENT OR THE PLAN.

 

THE COMPANY AND THE OPTIONEE IRREVOCABLY WAIVE ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF, RELATING TO, OR IN CONNECTION WITH THIS AGREEMENT OR THE PLAN.

 

Section 20.     Defined Terms/Construction. Capitalized terms used in this Agreement and not otherwise defined in this Agreement have the meanings ascribed to them in the Plan. Captions and titles contained in this Agreement are for convenience only and shall not affect the meaning or interpretation of any provision of this Agreement. Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular. Use of the term “or” is not intended to be exclusive, unless the context clearly requires otherwise. 

 

 

 

Section 21.     The Plan. The Optionee acknowledges having received a copy of the Plan. The Option is subject to all of the terms and provisions of the Plan, all of which are incorporated by reference. In the event of any inconsistency between the provisions of this Agreement and the provisions of the Plan, the provisions of the Plan shall govern.

 

 

 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first set forth above.

 

 

 

AVIRAGEN THERAPEUTICS, INC.

 

 

 

By: __________________________

 

Name:

 

Title:

 

 

 

 

 

OPTIONEE

 

 

 

 

 

_____________________________

 

[Name]

 

 

 

 

SCHEDULE A

 

 

 

	Name of Optionee:  	[ NAME ]	 
	 	 	 
	 	 	 
	 	 	 
	Option Number: 	000XXX 	 
	 	 	 
	 	 	 
	 	 	 
	Date of Grant:   	[GRANT DATE]	 
	 	 	 
	 	 	 
	 	 	 
	Option Exercise Price: 	$[_____] per share	 
	 	 	 
	 	 	 
	 	 	 
	Number of Shares Subject to Option: 	[______]	 
	 	 	 
	 	 	 

 

The Option is designated as an ___ Incentive Stock Option                 _ __ Non-Qualified Option.

 

 

 

	
			Vesting Date or Event

				
			Shares Vested

			 

			
	 	
			[____]

			 

			
	 	
			[____]

			 

			
	 	
			[____]

			 

			
	 	
			[____]

			 

			
	 	
			[____]

			 

			
	 	
			[____]

			 

			
	 	
			[____]

			 

			

 

 

 

 

Expiration Date:     [                ]

 

 

 

 

ANNEX 1

 

FORM OF ELECTION TO EXERCISE

 

(To be executed upon exercise of Option).

 

 

The undersigned elects to exercise the right pursuant to the stock option agreement between the undersigned and Aviragen Therapeutics, Inc. (the “Company”), dated as of _______________, 20_____ (the “Agreement”), to purchase _____ shares of the Company’s common stock, par value $0.10 per share (“Shares”).

 

 

Choose one or more of the following options:

 

 

 

	_____	Cash payment for __________ Shares in the amount of $_____________.
	 	 
	 	 
	 	 
	
			_____

				
			Payment for __________ Shares through a cashless exercise arrangement. The undersigned’s broker must forward the amount of cash necessary to purchase the Shares. Such broker will receive the Shares, and will forward the net proceeds of the cashless exercise to the undersigned.

			

 

 

 

The undersigned requests that certificates for the Shares be registered in the name of the undersigned.

 

 

 

Dated: _____________, 20____

 

 

 

_________________________

 

Optionee

 

__________________________

 

Social Security Number

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}]]